A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.

Clinical trial NCT07779798 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07779798
Sponsor: Crossbow Therapeutics, Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors Recurrent or Progressive Glioblastoma Relapse or Refractory Myeloid Malignancies

Start date: 2026-08-01
Primary completion: 2028-01-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.